Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: Awaking from bad dreams and nightmares

This article was originally published in Scrip

Executive Summary

The 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) wound down in Chicago this week and coincided with Gilead Sciences’ announcement of a second positive phase III clinical trial for its 'Quad' once daily treatment for HIV infection (scripintelligence.com, 21 September 2011). The two events are closely linked and the history between them should give investors in Gilead significant hope for the continued dominance of Gilead's anti-HIV franchise in the developed world. Reassuringly for believers in the rationality of the stock market, the assessment of Gilead's prospects by investors have been firmly based on the fundamental measures, namely the performance of its anti-HIV drugs and drug combinations relative to those of its rivals.

You may also be interested in...



Stockwatch: Repeating Past Mistakes At AbbVie

AbbVie’s latest, largest acquisition may be cast in a new light as the pandemic throws stock markets into turmoil and commercial prospects up in the air.

Stockwatch: Coronavirus And Commercialization

The prices of biotechnology and pharmaceutical sector indices continue to be comparatively robust in the face of big falls in global markets as investors expect new drugs and vaccines to be generated by the sector. While it is largely accepted that the life science sector will eventually ride to the rescue, bumper profits are far from guaranteed.

Stockwatch: Coronavirus And The Pharmaceutical Value Chain

Pharmaceutical shares are stronger than most as world stock markets dive downwards, but they are not immune to the coronavirus fallout. The effects will be felt by biopharma companies across many areas of their activity.

Topics

Related Companies

UsernamePublicRestriction

Register

SC014575

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel